» Authors » Jose Antonio Lluch-Rodrigo

Jose Antonio Lluch-Rodrigo

Explore the profile of Jose Antonio Lluch-Rodrigo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 31
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez-Lacort M, Munoz-Quiles C, Mira-Iglesias A, Lopez-Labrador F, Garces-Sanchez M, Escribano-Lopez B, et al.
Pediatrics . 2024 Oct; 155(1. PMID: 39363387
Objectives: This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTIs) in a large primary care network in Spain,...
2.
Juaneda J, Estrella-Porter P, Blanco-Calvo C, Orrico-Sanchez A, Antonio Lluch-Rodrigo J, Pastor-Villalba E
Vaccines (Basel) . 2024 Jun; 12(6). PMID: 38932352
Public funding of vaccines may enhance vaccination rates, co-administration, and timeliness. The impacts of including the serogroup B meningococcus vaccine (MenB) into the national immunisation schedule on vaccination rates, co-administration...
3.
Estrella-Porter P, Blanco-Calvo C, Lameiras-Azevedo A, Juaneda J, Fernandez-Martinez S, Gomez-Pajares F, et al.
Vaccine . 2024 Jun; 42(22):126030. PMID: 38834430
Respiratory syncytial virus (RSV) represents a high burden of disease in children and the primary cause of hospitalization, especially in children under 1 year old. In the Valencian Community (Spain),...
4.
Lopez-Lacort M, Munoz-Quiles C, Mira-Iglesias A, Lopez-Labrador F, Mengual-Chulia B, Fernandez-Garcia C, et al.
Euro Surveill . 2024 Feb; 29(6). PMID: 38333937
The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan...